MBX Biosciences, Inc. priced its initial public offering at $18.00 a share, offering 11,108,055 shares of common stock, to list on the Nasdaq Global Select Market under the symbol MBX. It filed a Form S-1 registration statement for an initial public offering on August 23, 2024. As of November 7, 2026, its final prospectus is on file (Form 424B4, September 25, 2025).
Who owns MBX Biosciences, Inc.?
Sell to companies like MBX Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
MBX Biosciences, Inc. filed a Form S-1 registration statement for an initial public offering on 2024-08-23. It has amended it 2 times. It filed its final prospectus on 2025-09-25, at a public offering price of $18.00 per share. Each fact below is quoted from the filing named with it.
Also on the record for MBX Biosciences, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 15% of the class | 5%+ stakes | Source |
| October 22, 2026 | Leadership change: Peter Radovich appointed, Director | — | Leadership changes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | 3.64% of the class | 5%+ stakes | Source |
| August 10, 2026 | Stake report, Schedule 13D/A, by Frazier Life Sciences Public Fund, L.P. | 11.7% of the class | 5%+ stakes | Source |
| August 10, 2026 | Stake report, Schedule 13D/A, by ORBIMED ADVISORS LLC | 6.4% of the class | 5%+ stakes | Source |
| July 29, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.5% of the class | 5%+ stakes | Source |
| July 13, 2026 | Leadership change: Steven Hoerter appointed, President and Chief Executive Officer | — | Leadership changes | Source |
| July 8, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 11.2% of the class | 5%+ stakes | Source |
| July 8, 2026 | Stake report, Schedule 13G/A, by Wellington Management Group LLP | 10.5% of the class | 5%+ stakes | Source |
| June 24, 2026 | Stake report, Schedule 13G, by Paradigm BioCapital Advisors LP | 5.2% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G, by FMR LLC | 6.2% of the class | 5%+ stakes | Source |
| April 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 4.8% of the class | 5%+ stakes | Source |
Check before you invest in MBX Biosciences, Inc.: the warning signs and who's behind it, free.
Free to see. No signup.
Keep reading
More on MBX Biosciences, Inc. and the records around it.
MBX Biosciences, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Leadership changes Jul 2026
- Who owns it
Companies that share a holder
- Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. also filed stake reports on 2 other companies: Korsana Biosciences, Inc. (Sep 2026), ProMIS Neurosciences, Inc. (Aug 2026)
- New Enterprise Associates 17, L.P. also filed stake reports on 4 other companies: Monte Rosa Therapeutics, Inc. (Jul 2026), Inventiva S.A. (Apr 2026), Korro Bio, Inc. (Mar 2026)
- Paradigm BioCapital Advisors LP also filed stake reports on 22 other companies: Obsidian Therapeutics, Inc. (Oct 2026), Spyre Therapeutics, Inc. (Oct 2026), Tyra Biosciences, Inc. (Sep 2026)
Also filing to list on the Nasdaq Global Select Market
IPO filings on the Nasdaq Global Select Market in Q3 2025, newest first.
- Gemini Space Station, Inc. (Sep 2025)
- CARLSMED, INC. (Jul 2025)
Watch MBX Biosciences, Inc.
Get an email when MBX Biosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on MBX Biosciences, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on MBX Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on MBX Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 25 records.
What the filings say
Listing
Our common stock is listed on the Nasdaq Global Select Market, or Nasdaq, under the symbol “MBX”.From the 424B4 filed 2025-09-25
Shares offered
We are offering 11,108,055 shares of our common stock.From the 424B4 filed 2025-09-25
Offering price
the public offering price of $18.00 per share;From the 424B4 filed 2025-09-25
Underwriters
Morgan Securities LLC and Jefferies LLC are acting as joint book-running managers of the offering, and as representatives of the underwriters.From the 424B4 filed 2025-09-25
Use of proceeds
We intend to use the net proceeds of this offering, together with our existing cash and cash equivalents and short-term investments, to fund the continued development of canvuparatide, imapextide, and MBX 4291, as well as our other obesity preclinical stage program, our discovery research and development activities and additional clinical development and for general corporate purposes and working capital.From the 424B4 filed 2025-09-25
Net loss or income
Our net loss was $26.1 million and $32.6 million for the years ended December 31, 2022 and 2023, respectively.From the S-1/A filed 2024-09-09
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2024-08-23 | Registration statement filed | S-1 |
| 2024-08-30 | Registration statement amended | S-1/A |
| 2024-09-09 | Registration statement amended | S-1/A |
| 2025-09-22 | Registration statement filed | S-1 |
| 2025-09-25 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for MBX Biosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.